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3Condensation: 
Out of a series of injectible sealants for fetal membranes, mussel-mimetic hydrogel adhesive 
was not toxic and capable of closing trocar punctures ex vivo. 
4Injectible sealants for fetal membrane repair: Bonding and toxicity in vitro
Grozdana Bilic, Carrie Brubaker, Phillip B. Messersmith, Ajit S. Mallik, Thomas M. Quinn, 
Elisa Done, Leonardo Gucciardo, Steffen M. Zeisberger, Roland Zimmermann, Jan Deprest, 
and Andreas H. Zisch
Objective: This study was undertaken to test injectible surgical sealants that are 
biocompatible with fetal membranes, eventually for closure of iatrogenic membrane defects. 
Study Design: Dermabond, Histoacryl, Tissucol fibrin glue, and three types of in situ
forming poly(ethylene glycol)-based polymer hydrogels were tested for acute toxicity upon 
direct contact with fetal membranes for 24h. For determination of elution toxicity, extracts of 
sealants were incubated on amnion cell cultures for 72h. Bonding and toxicity was assessed
through morphological and/or biochemical analysis. 
Results: Extracts of all adhesives were non-toxic for cultured cells. However, only Tissucol
and one type of poly(ethylene glycol)-based hydrogel, mussel-mimetic tissue adhesive, 
showed efficient, non-disruptive, non-toxic bonding to fetal membranes. Mussel-mimetic 
tissue adhesive applied over membrane defects created with a 3.5 mm trocar accomplished 
leak-proof closure that withstood membrane stretch in an in vitro model. 
Conclusion: 
A synthetic hydrogel-type tissue adhesive evolved as potential sealing modality for iatrogenic 
membrane defects that merits further evaluation in vivo. 
Key words: fetal membranes, fetoscopy, iatrogenic PPROM, prophylactic plugging, tissue 
adhesive, fetoscopic access, fibrin, DOPA
5Introduction
Invasive diagnostic and therapeutic fetal procedures are frequently complicated by amniotic 
fluid leakage, separation of amnion and chorion, or even frank iatrogenic preterm premature 
rupture of the fetal membranes (iPPROM). For fetoscopic procedures, rates of iPPROM 
range between 6 to 45%,1 but in a trial of fetal endoscopic tracheal occlusion for severe 
congenital diaphragmatic hernia a 100% rate was reported.2 Since these procedures are 
usually performed in the second trimester of pregnancy, iPPROM usually occurs at an early 
gestational age. Hence, the associated morbidity and mortality may compromise the expected
benefits of the intervention. iPPROM is therefore a serious limitation for prenatal fetal 
surgery. Clinically, measures of plugging membranes after established rupture as well as of 
preventive plugging of fetoscopic access sites have been undertaken, as reviewed before.3,4
For closure after obvious iatrogenic rupture, intra-amniotic injection at the puncture site of 
maternal platelets mixed with fibrin cryoprecipitate ('amniopatch') has evolved as promising 
route to seal.5,6 But increasing efforts have been concentrated on taking action before rupture 
rather than reacting after established or symptomatic rupture. Several preventive plugging 
methods using dry collagen and gelatin plugs or liquid blood-derived sealants have already 
been clinically investigated. Early experience encourages this avenue for prevention of 
iPPROM. A 2006 report on a 27 patient cohort found a low 4.2% rate of postoperative 
PPROM upon gelatin plug (Gelfoam) insertion upon port retrieval in endoscopic fetal 
surgery.7 In another small clinical study, sequential injection of platelets, fibrin glue and 
powdered collagen slurry directly to the puncture site successfully prevented amniotic fluid 
loss after endoscopic procedure.8 Still, the positive outcome with these methods await to be 
reproduced in other centers. Of note, collagen fleece plugs (Lyostypt) are now routinely used 
for preventive plugging of membrane defects following fetoscopic endoluminal tracheal 
occlusion for in utero therapy of congenital diaphragmatic hernia in one center of the authors, 
6in Leuven. Other preventive plugging techniques such as scaffold-type plugs manufactured 
directly from decellularized amnion tissue have been so far only evaluated in animal models1, 
2.9,10 Further, laser welding, and pre-emptive placement of synthetic surgical sealants before 
fetoscopic access were evaluated in vitro.11,12 There is evidence that spontaneous healing is 
slow, if not absent in fetal membranes. Histological follow-up of fetoscopic puncture defects 
in membranes of human patients several months after the procedure showed that the defects 
did not close by healing.13 The amnion layer contains few cells and lacks blood vessels 
completely, which makes healing response in this layer unlikely. Our own trials in rabbits of 
prophylactic plugging of membrane defects with decellularized amnion scaffolds showed 
effective sealing but without detectable signs of biological repair after a 1-week period,9
which is the maximum achievable in this experimental model. Recent studies in the 
midgestational rabbit observed signs of beginning healing of membrane defects upon addition 
of platelets or amniotic fluid cells to collagen plugs;14,15 the jury is still out whether this effect 
could assume relevant degrees of healing long-term. The main criteria for a prophylactic plug 
material may be to present an immediate, non-toxic and ideally, durable physical barrier to 
amniotic fluid, and not necessarily induction of biological healing. With this strategy in mind, 
we examined five liquid synthetic sealants, namely two types of cyanoacrylate glues and 
three poly (ethylene glycol-based) hydrogel-type polymers, for their principal aptitude for 
fetal membrane repair. Gluing of defective tissue in moist/wet conditions or even underwater 
presents a particular challenge. In the present study, we addressed gluing to moist, intact fetal 
membranes. Alkyl-cyanoacrylate glues were chosen on the basis of their well-known strong 
bonding to tissue, and their use as tissue adhesives in surgical and traumatic wound repair.16
Our choice of three synthetic poly (ethylene glycol) (PEG)-based hydrogel sealants, 
photopolymerizable gel, mussel-mimetic adhesive and commercial SprayGel was based on 
data showing their interfacial bonding to various tissues, and the possibility to deliver them in 
7minimally invasive liquid form for gelation in situ.17-19 Two types of PEG-based hydrogels 
under present study, SprayGel and photopolymerized PEG, were already used clinically. 
SprayGel has been clinically used as bioabsorbable anti-adhesion barrier in patients 
undergoing myomectomy.20 A clinically approved formulation of photopolymerized PEG 
hydrogel sealant, FocalSeal-L sealant, proved successful for closure of pulmonary air leaks in 
the lung occuring at cardiac operations.21 For the experimental mussel-mimetic adhesive 
hydrogel formulation of present study, no clinical data exist yet. Here we estimated 
applicability of these synthetic polymers as sealants on fetal membranes based on their 
bonding to fetal membranes and toxicity in vitro, using the biosurgical Tissucol fibrin glue 
sealant as internal reference.  
Material and methods
Membrane collection and amnion cell isolation 
The Ethical Committee of the District of Zurich approved the protocol (study Stv22/2006). A 
total of 15 fetal membranes were collected with written patient consent from elective 
caesarean sections. Mean gestational age was 38 ±1 weeks in the absence of labor, preterm 
rupture of membranes, chorioamnionitis, or chromosomal abnormalities. Fetal membrane 
pieces of 150-200 cm2 were collected. Human amnion epithelial (hAEC) and amnion 
mesenchymal cells (hAMC) were isolated and cultured as described previously.9
Sealants
Alkyl-cyanoacrylate glue sealants: Dermabond (Ethicon Inc., Norderstedt, Germany) and 
Histoacryl (B. Braun GmbH, Tuttlingen, Germany) are 2-octyl cyanoacrylate monomer and 
n-butyl-2-cyanoacrylate monomer, respectively. The formulations possess syrup-like 
viscosity. These glue act through anionic polymerization of hydroxyl groups from the minute 
8amounts of moisture normally present on actual surfaces that are glued, including biological 
surfaces. Indeed, cyanoacrylate glues are known to be extremely adhesive to tissue.16 Water 
act as a catalyst to accelerate this polymerization. The polymerization oocurs within minutes 
after application to tissue. The resulting resin is waterresistant. Both Dermabond and 
Histoacryl are marketed as topical skin adhesives to hold skin edges of wounds from surgical 
incisions. As specified by the manufacturer of Dermabond, it is not for application on wet 
wounds. 
Hydrogel sealants: 
SprayGel (Confluent Surgical, Inc., Waltham, MA) is a sprayable anti-adhesion barrier 
polymer that consists of two synthetic liquid precursors that when mixed together, rapidly 
cross-link to form a solid absorbable hydrogel in situ. The first precursor is a modified 
polyethelene glycol (PEG) with terminal electrophilic esters groups while the other precursor 
solution contains PEG that has nucleophilic amine groups.22 SprayGel is marketed outside the 
US for use in abdominal and pelvic surgical procedures. It has been clinically also tried to 
reduce adhesion formation after ovarian surgery.19 SprayGel was deposited at the fetal 
membranes through the air pump-assisted SprayGel Laparoscopic Sprayer. The gel is 
formulated to remain adherent on the site of application for approximately five days
whereafter it is absorbed by way of gradual hydrolysis. 
Photopolymerized PEG hydrogel sealant (pPEG) was formed via in situ interfacial 
photopolymerization of PEG diacrylate precursor of average molecular weight 700 Da 
(Sigma) according to a previously described gelation protocol.18 Fetal membranes were 
flushed with a tissue adsorbing photoinitiator eosin Y (1mM in 10mM 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid, pH 7.4, 0.15M sodium chloride; (HEPES-
buffered saline). Then solution containing 10% PEG diacrylate and the co-catalysts 
triethanolamine (13.2 µL/mL) and 1-vinyl-2- pyrrolidine (3.5µL/mL) in HEPES-buffered 
9saline was applied to the membranes and photopolymerized by irradiation at 480-520 nm and 
75mW/cm2 for 1 min from a portable Cermax xenon fiber optic light source, CXE300 (ILC 
Technology Inc., USA). 
The mussel-mimetic tissue sealant is a catechol-functionalized poly(ethylene glycol) (cPEG) 
whose molecules crosslink into a hydrogel by way of oxidation after addition of sodium 
periodate.23 The composition and synthesis of cPEG is described elsewhere.24 For gelation, 
equal volumes of the polymer precursor solution (300 mg/mL in phosphate-buffered saline 
(PBS)) and the cross-linking solution (12 mg/mL sodium periodate in water) were mixed 
using a dual syringe applicator device equipped with a blending connector with mixer 
(FibriJet; Micromedics, Inc., St. Paul, MN). Hydrogels prepared from cPEG polymer and its 
derivatives are expected to possess the ability to secure very strong adhesion to almost any 
surface, even under wet conditions. The presence of catechol in cPEG sealant was inspired by 
the wet adhesive properties conferred by the catechol side chain of 3,4-
dihydroxyphenylalanine (DOPA) amino acid, which is found in high concentrations in the 
foot proteins of marine or freshwater mussels.25,26
Tissucol Duo S fibrin glue (Baxter AG, Volketwil, Switzerland) is a biological two-
component adhesive that forms by mixing of human plasma cryoprecipitate solution with 
thrombin solution. The chemical and physical polymerization of the main component of 
fibrin glue sealant, fibrinogen, mimics the last step of the natural blood clot formation; Fibrin 
glue is clinically widely applied as hemostatic surgical sealant or adjunct to suture.27
Toxicity tests
Toxicity of sealants for fetal membrane cells was evaluated using direct contact and elution 
tests, as per International Organization for Standardization (ISO) 10993-5 guidelines. 
Direct contact cytotoxicity: 
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Direct contact studies were performed with term fetal membranes obtained from three cases. 
The amniotic layer was chosen for sealant application (Fig. 1A) because this layer was 
proposed to be the strength-bearing layer of fetal membranes and major determinant for 
PPROM.28 2x1cm patches of freshly harvested fetal membranes were placed into wells of 6-
well plates with amnion layer up. The sealants were applied at 50µl and 200µl volumes 
except cPEG adhesive which was only tested at 200µl volume because of limited material. 
Membranes covered with sealant were covered with 3 mL culture medium (Ham’s F-
12/DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin) 
and cultured for 24h at 37°C. Controls were untreated membranes that were immediately 
processed for histology (control '0') or cultured for 24h (control '24'). After 24h, the treated 
membranes were fixed in 4% formaline, embedded in paraffin and sectioned for histology. 
Deparaffinized sections were either stained with hematoxylin-eosin (H/E), or stained for 
apoptotic cells using TUNEL technology (Terminal deoxynucleotidyl transferase dUTP nick 
end labeling; In Situ Cell Death Detection Kit, Fluorescein (Roche Diagnosticss Gmbh, 
Mannheim, Germany). For total cell counts, all cell nuclei were counterstained with 4',6-
diamidin-2'-phenylindol-dihydrochlorid (DAPI; Sigma, Buchs, Switzerland). The histologic 
images were taken with a Zeiss Axiovert 200M fluorescent microscope (Carl Zeiss, 
Goettingen, Germany) equipped with an Zeiss AxioCam MRc digital camera and analysed 
with AxioVision Rel. 4.5 software (Carl Zeiss). Apoptotic and total cell counts were acquired 
from fluorescence micrographs using automated image analysis software ImageJ 1.34s
(National Institute of Health, Bethesda, ML). One tissue section per case was analysed, 
taking four optical fields per section for analysis. 
Elution toxicity: 
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To test potential toxicity of soluble compounds released from the sealants for cultured 
amnion cells, two types of extractions were performed: First, extracts from sealant alone. For 
that, 0.2 mL of glue/hydrogel were incubated for 24h in 3 mL Ham's-F12/DMEM/FCS 
culture medium. Second, extracts from sealants applied to membranes. The second method 
was to resolve whether treatment of membranes could result in production of cytokines by 
hAECs and hAMCs that add to induction of apoptosis. For that 0.2 mL glue /hydrogel sealant 
were applied to 2 x 1 cm pieces of fetal membranes and incubated for 24h in 3 mL Ham's-
F12/DMEM/FCS culture medium. The extracts were collected and stored at -80°C until use 
for culture. Amnion cells from four human cases were subjected for assay of toxicity, and for 
each sealant the extraction test was evaluated in triplicate. 2x104 hAECs or hAMSCs were 
seeded per well of 48 well plates and cultured in Ham's/F12/DMEM/FCs standard medium 
near to confluence. Then medium was removed, and cells overlaid with 0.4 mL of extracts 
from either sealant alone, or extract from membranes+sealant. Extracts from untreated 
membrane samples from the same patients in standard culture medium served as controls. 
The cells were cultured for 72h. Cell morphology was assessed microscopically, and degree 
of cell detachment and lysis was judged qualitatively. Following evaluations were performed: 
(i) For total cell count, hAECs and hAMSCs were stained with DAPI (ii) Apoptotic cells 
were detected with in situ Cell Death Detection Kit (Roche). Total cell counts and apoptotic 
cell counts were acquired from fluorescence fluorescence micrographs using automated 
image analysis software ImageJ 1.34s (National Institute of Health, Bethesda, ML). (iii) 
Areas of individual cells were measured using LeicaQ Win Image Analysis software (Leica 
Imaging System Ltd, Cambridge, UK). (iv) Live/dead cell staining was performed. For that, 
amnion cell cultures were incubated for 3 min with a mix of calcein to detect live cells and 
ethidiumbromide homodimer to detect dead cells at 1µM and 2µg/ml, respectively. All 
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experiments were performed in triplicates and four optical fields were analysed for each 
sample.
Sealing of fetal membranes lesion in vitro
Sealing performance of cPEG adhesive was tested on trocar punctures through fresh fetal 
membranes. For that, wet fetal membranes were flat-mounted with the amnion side up on a 
commercial motorized mechanical stretch device named 'The Cellerator' (Cytomec GmbH, 
Switzerland; http://www.cytomec.com/) that we further adapted for use in fetal membrane 
studies (Fig. 4A). The Cellerator device permits fetal membranes expansion in a radial
fashion keeping the strength of stretch uniformly distributed along the mounted membrane. 
Puncture lesions were created with a three-side pointed Ø 3.5mm trocar (Richard Wolf 
GmbH, Knittlingen, Germany). The punctured membranes were kept moistened with excess 
PBS, before approximately 0.5 mL cPEG adhesive was applied over the membrane defect. 
Two minutes after treatment, membranes were further stretched by about 30% of their 
original area. To demonstrate leak-proof sealing, the membranes, still mounted in the device, 
were overlaid with 0.3 L water. After the leak-proof test, the area of the treated membrane 
defect was excised and processed for standard histology. Histologic sealing was estimated 
microscopically from hematoxylin/eosin stained sections by the ability of the sealant to form 
a continuous bridge between the wound edges. 
Statistical analysis
Data are shown as mean ± SEM. Two-tailed unpaired t test was performed using GraphPad 
Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA). Significance 
level was set at p< 0.05.
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Results
Contact-mediated effect of sealants for membrane morphology  
Histology in figure 1 illustrates the effect of treatment for overall membrane morphology for 
the six bioadhesives under test. Fibrin glue and cPEG adhesive formed a continuous layer 
tightly bound to tissue (Figure 1B, arrow heads). The normal membrane morphology 
appeared maintained, with the amnion epithelial layer intact. SprayGel and pPEG exhibited 
partial or no binding to tissue, respectively. In the case of pPEG, we found the hydrogel layer 
sloughed into the culture medium shortly after immersion of the membranes in culture 
medium. Binding of Dermabond and Histoacryl to fetal membranes resulted in disruption of 
the amnion layer and change of overall membrane morphology, which was more pronounced 
for Dermabond. The effects of 50µl treatment volumes were very similar (not shown). 
Direct contact-induced apoptosis 
Fig. 2A depicts fluorescence micrographs of apoptotic cells (TUNEL) and all cell nuclei in 
tissue (DAPI) in fetal membranes treated with Dermabond. Fig. 2B gives the apoptosis rates 
for the 200µl test series. In untreated reference membranes, the apoptosis rate increased to 
17±2% during the 24h incubation. Treatment with fibrin glue, cPEG adhesive, and pPEG did 
not enhance apoptosis over control. Dermabond and SprayGel treatment significantly 
(p< 0.05) enhanced apoptosis by 3.9-fold to 69±13 % and by 1.9-fold to 34±3% over the 
control, respectively. Histoacryl treatment produced a 1.6-fold increase of apoptosis rate to
28±6%, which was not significant over control. The outcome in the 50µl test series was 
similar, except that at lower dose, the apoptosis rate by SprayGel was not significantly over 
control (Fig. 2C). 
Elution toxicity of sealants for primary cultures of amnion cells
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To test for toxicity from compounds released from the sealants, we investigated cell lysis, cell 
detachment and change of cell shape in hAECs and hAMCs that were grown in extracts of 
sealants in culture medium. None of the cultures, except those grown in extracts of 
Dermabond, appeared affected by toxic compounds after 24h and 72h. There was no 
difference between extracts prepared from sealant alone, or from sealants applied to 
membranes. Fig. 3 depicts micrographs of hAECs and hAMCs cultures prepared from four 
fetal membranes after incubation with extracts of Dermabond. hAMSC were not affected in 
any condition as estimated by cell size and cell number. Only in the condition of hAECs 
grown in Demabond, we observed modest, insignificant reduction of cell size and number. 
Cell size of hAECs cultured in Dermabond extracts were 1138±166 µm2 (n=193 cells) versus 
1423±196 µm2 (n=168 cells); cell numbers in the Dermabond condition were lower (323±31 
cells/optical field) compared to control cultures (424±47 cells/optical field). TUNEL staining 
of hAEC and hAMC cultures did not show any induction of apoptosis, and live/dead staining 
with calcein and ethidium bromide showed that practically all cells in culture were alive (not 
shown). Overall, extracts of sealants behaved non-toxic for amnion primary cultures. 
Sealing of puncture lesions in vitro
Our stratification revealed that cPEG adhesive and Tissucol fibrin glue alike show strong 
bonding to fetal membranes and behave non-toxic, which are two basic prerequisites for 
prospective application for repair. cPEG adhesive is a new formulation that has never been 
tested for sealing of membrane defects before. We tested 0.5 mL cPEG adhesive for closure 
of Ø 3.5mm trocar puncture wounds in fetal membranes mounted in a biomechanical test 
device (Fig. 4). Successful closure was achieved in all three test cases. Application of cPEG 
tissue adhesive over the defect resulted in an immediate leak-proof membrane seal that 
remained functional upon further radial stretch of the membranes. Fig. 4C shows 
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representative histologic images from two locations of a puncture lesion sealed with cPEG 
tissue adhesive. Histology confirmed that the cPEG tisssue adhesive connected the wound 
edges over a distance of approximately 6 mm, which was the maximum diameter in such 
lesions. cPEG tissue adhesive was found adhered to both the amnion side, the application side 
in these experiments, but as well to the chorionic side of the membranes, Thus, sealant passed 
through the lesion and spread underneath the membranes. 
Comment
Three commercial and two experimental synthetic sealants were tested along with Tissucol 
fibrin glue for applicability on fresh, moist human fetal membranes, using interfacial bonding 
and cytotoxicity in vitro for read out. Four of the five synthetic sealants failed to meet the 
combined requirements of membrane bonding and non-toxicity which excludes them for this 
type of repair. Our screen identifies one synthetic hydrogel, cPEG tissue adhesive, that 
exhibits bonding to membranes and non-toxic characteristics that favorably compare to fibrin 
glue. Ex vivo, cPEG adhesive demonstrated repair capacity for 3.5 mm trocar punctures, 
accomplishing immediate leak-proof sealing, which may warrant further evaluation in vivo.
Membrane bonding properties of the six bioadhesives under this study demonstrated large 
variability. Cyanoacrylate-based glues seem inappropriate for application on fetal 
membranes. The observation of their strong bonding to fetal membrane tissue was 
accompanied by obvious damage to the amnion epithelial layer and disruption of membrane 
structure, especially the amnion layer. Amniotic integrity is considered more important than 
chorionic integrity because the amnion is thought to have greater tensile strength.28 In 
addition, Dermabond, but not Histoacryl, exhibited significant cytotoxicity. Two of the PEG-
based hydrogel polymers, photopolymerizable PEG hydrogel and SprayGel, failed to bond to 
fetal membranes sufficiently. Photopolymerized PEG-diacrylate hydrogels were previously 
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used to create thin intravascular barriers to block thrombus deposition after balloon-induced 
arterial injuries in animal models, and firm adhesion of the PEG-diacrylate hydrogel to 
arterial walls was reported.18,29 Although the pPEG and SprayGel hydrogels could be 
polymerized on fetal membranes, they sloughed off from the membranes quickly after the 
immersion of the membranes in culture medium. Neither the hydrogel itself nor the one 
minute laser irradiation required for hydrogel curing produced adverse effects for membrane 
integrity. In the case of SprayGel, the resulting polymer layer was not continuous, weakly 
bonded to membranes, and cytotoxic. 
cPEG adhesive, on the other hand, displayed membrane bonding and compatibility 
comparable to that of Tissucol fibrin glue. cPEG adhesive is a two-component, self-
crosslinking polymer with the remarkable property to form strong and durable bonds to many 
surfaces even in wet environment. Creation of cPEG adhesive has been inspired by the 
composition of liquid adhesives secreted by marine mussels, which allow these organisms to 
firmly anchor themselves to any surface. The wet adherence of native mussel adhesive 
proteins rests on the unusual amino acid residue 3,4 dihydroxyphenylalanine (DOPA) that is 
present in high concentrations in the foot proteins of mussels.25,30,31 Work in the group of one 
of the authors (P.B.M.) and other laboratories has demonstrated that the wet adherence ability 
of mussel foot proteins can be conferred onto synthetic polymers by way of incorporating 
DOPA and DOPA analogues.17,23,32,33 Indeed, previous work has demonstrated that DOPA-
functionalized PEG precursors cross-link via sodium periodate-mediated oxidation to form 
adhesive hydrogels with high rigidity.23 In the present study, the cPEG polymer contains a 
simplified mimic of DOPA in the form of a reactive catechol group, generating a new 
variation of the adhesive that can be used under the same preparative conditions.24 This 
formulation possesses both appealing and potentially problematic characteristics for use as 
fetal membrane sealant. Properties that we consider favorable are fast gelation (under a 
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minute); very slow hydrolysis over several months, allowing for durable sealing; and 
excellent tissue adhesion. Recent analysis revealed that bonds formed by a mussel-mimetic 
adhesive between porcine dermal tissues were several times stronger than those formed by 
fibrin glue.17 Possible disadvantages of the present formulation are the use of the strong 
oxidizing reagent sodium periodate as trigger of polymerization, which is known to be 
strongly irritating. However, a rapid chemical reaction ensues upon contact of periodate with 
pPEG, which ultimately gives rise to chemical crosslinking of the polymer but also results in 
reduction of periodate to less harmful oxidative species.17 Issues of in vivo irritation and 
inflammatory tissue response to cPEG adhesive are addressed in another study involving the 
use of cPEG for transplantation of mouse islets.24 While the results of that study, like the data 
reported herein, reveal favorable in vivo biocompatibility, ultimately the full effects of cPEG 
on uterine contractions and fetal survival and integrity will require further evaluation in the 
rabbit model of midgestation. 
In summary, this study points to a new hydrogel formulation with appealing properties for 
membrane repair. Still, we are aware that such data ex vivo are limited in their ability to 
predict success in the in vivo situation. 
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Figure legends
Fig 1. Histologic assessment of bonding properties and effect for membrane morphology of 
bioadhesives. (A) Sealants were applied on the amniotic site of fetal membranes. (B) Images 
of hematoxylin/eosin-stained cross-sections of fetal membranes that were incubated with 
sealants for 24h. Fat arrows mark the hydrogels, thin arrows mark the damage to the amnion 
layer by Dermabond and Histoacryl. Bar size: 100 µm. 
Fig. 2. Direct contact-mediated cytotoxic effect of sealants for fetal membranes. (A) 
Fluorescence micrographs of apoptotic cells (green) and total cells (DAPI). The example 
shows a section of a membrane treated with Dermabond. (B) Apoptosis rates in membranes 
treated with 200µl sealant volumes. (C) Apoptosis rates in membranes treated with 50µl
sealant volumes. Values are mean ± SEM. * indicates p< 0.05.
Fig. 3. Test of elution toxicity of sealants for primary cultures of amnion cells from four 
human cases. Phase micrographs show and hAECs and hAMSCs cultured for 24h in extracts 
of Dermabond in culture medium. Bar size: 100 µm.
Fig. 4. Ex vivo sealing of fetal membrane defects with mussel-mimetic adhesive. (A) Fetal 
membranes mounted in a computerized radial stretch device before and after stretch. (B) 
Through-thickness puncture wounds (arrow) were created on fresh fetal membranes with a Ø 
3.5mm trocar. Approximately 0.5 mL of adhesive was applied over the defect. The white line 
marks the area of sealant. (C) Hematoxylin/eosin stained cross-section of a trocar puncture 
treated with cPEG adhesive. The hydrogel appears as ribbon-like structure that bridges the 
puncture edges. The bottom image shows a cross-section of the same lesion at a narrow 
location. 
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